ОбзорГрафикНовостиTraderScreen

BVT Put 145 IDP 20.12.2024/  DE000VD4A7T5  /

Frankfurt Zert./VONT
19.11.2024  14:02:24 Изменение-0.030 Бид14:10:58 Предложение14:10:58 Базовый актив Цена исполнения Дата истечения Тип опциона
0.280EUR -9.68% 0.290
Величина цены спроса: 35,000		 0.310
Величина цены предложения: 35,000		 BIOGEN INC. DL -,000... 145.00 - 20.12.2024 Put
TeleTrader 30.10 Biogen's Q3 revenue down 3% to $2.5 billion
TeleTrader 01.08 Biogen books $2.5 billion in Q2 revenue
GlobeNewswire 30.07 New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecane...
GlobeNewswire 30.07 Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Path...
GlobeNewswire 26.07 Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
GlobeNewswire 02.07 Biogen Completes Acquisition of Human Immunology Biosciences
GlobeNewswire 28.06 “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
GlobeNewswire 24.06 TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union
GlobeNewswire 10.06 FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application f...
GlobeNewswire 03.06 Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of ...
GlobeNewswire 30.05 Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a R...
GlobeNewswire 22.05 Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...
GlobeNewswire 21.05 Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
GlobeNewswire 16.05 Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...
GlobeNewswire 15.05 Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire 02.05 Biogen Reports Progress on Corporate Responsibility Priorities
GlobeNewswire 25.04 Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...
TeleTrader 24.04 Biogen posts Q1 revenue of $2.3 billion
GlobeNewswire 23.04 Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire 02.04 ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer
GlobeNewswire 06.03 New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...
GlobeNewswire 04.03 Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire 23.02 Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...
TeleTrader 13.02 Biogen's Q4 revenue falls 6% to $2.4 billion
GlobeNewswire 12.02 Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...